Beyond statins, one drug lowered heart attack risk by 20%
Amgen's Repatha demonstrates a lower risk of heart attacks compared to ezetimibe in a large real-world study.
9 trends tracked about this subject — the full history, oldest to newest below.
Amgen's Repatha demonstrates a lower risk of heart attacks compared to ezetimibe in a large real-world study.
Amgen reports that combining Imdelltra with Imfinzi reduces the risk of death by 58% for patients with first-line extensive stage small cell lung cancer.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
U.S. stocks tumble as crude oil approaches $100 per barrel and inflation data approaches.
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.